2022
DOI: 10.1016/j.jneuroim.2021.577767
|View full text |Cite
|
Sign up to set email alerts
|

Eculizumab treatment for myasthenia gravis subgroups: 2021 update

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 64 publications
1
5
0
Order By: Relevance
“…Currently, a number of complement components are assessed as drug targets in above‐mentioned diseases. A few treatments were granted regulatory approval, the most prominent one being eculizumab, a monoclonal antibody inhibiting C5 in PNH, aHUS, generalized myasthenia gravis, and neuromyelitis optica 10,15,16 . Despite frequent intravenous dosing, not all patients reach sustained complement inhibition, and this antibody is among the most expensive therapies available nowadays 17 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, a number of complement components are assessed as drug targets in above‐mentioned diseases. A few treatments were granted regulatory approval, the most prominent one being eculizumab, a monoclonal antibody inhibiting C5 in PNH, aHUS, generalized myasthenia gravis, and neuromyelitis optica 10,15,16 . Despite frequent intravenous dosing, not all patients reach sustained complement inhibition, and this antibody is among the most expensive therapies available nowadays 17 .…”
Section: Introductionmentioning
confidence: 99%
“…A few treatments were granted regulatory approval, the most prominent one being eculizumab, a monoclonal antibody inhibiting C5 in PNH, aHUS, generalized myasthenia gravis, and neuromyelitis optica. 10,15,16 Despite frequent intravenous dosing, not all patients reach sustained complement inhibition, and this antibody is among the most expensive therapies available nowadays. 17 The concomitant blockage of C5b and MAC formation constitutes a safety liability due to increased risk of bacterial infections.…”
Section: Introductionmentioning
confidence: 99%
“…The recent severe infection and the application of mechanical ventilation were not optimal circumstances for complement-blocking therapy. However, after the patient improved and was also diagnosed with PNH, both diseases required treatment [ 3 , 13 , 16 , 17 ]. The only logical and effective treatment choice was complement-blocking therapy.…”
Section: Discussionmentioning
confidence: 99%
“… 4 Alternatively, C5b forms a complex with complement C6 and other complement components to produce C5b-9, a membrane attack complex (MAC) that eventually disrupts the cell membrane of target cells. Several reports indicate that C5a and C5b-9 are involved and play a critical role in several autoimmune/inflammatory disorders such as paroxysmal nocturnal hemoglobinuria (PNH), 5 , 6 anti-neutrophil cytoplasmic antibody-associated vasculitis, 7 , 8 atypical hemolytic uremic syndrome (aHUS), 9 systemic lupus erythematosus, 10 , 11 rheumatoid arthritis (RA), 12 ischemia/reperfusion injury, 13 myasthenia gravis (MG), 14 , 15 neuromyelitis optica spectrum disorder (NMOSD), 16 and Guillain-Barré syndrome. 17 In addition, C5a and C5b-9 are also implicated in antibody-mediated rejection.…”
Section: Introductionmentioning
confidence: 99%